Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma†
AbstractMetastatic melanoma is a recalcitrant tumor. Although “targeted” and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use of surgical orthotopic implantation (SOI). Promising results have been obtained with regard to identifying effective approved agents and experimental therapeutics, as well as combinations of the two using the melanoma PDOX model. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Hoffman, R.M. Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma. Int. J. Mol. Sci. 2017, 18, 1875.
Hoffman RM. Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma. International Journal of Molecular Sciences. 2017; 18(9):1875.Chicago/Turabian Style
Hoffman, Robert M. 2017. "Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma." Int. J. Mol. Sci. 18, no. 9: 1875.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.